Tagged with EU

Switzerland Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines the importance of Switzerland as one of the French company’s key markets, the challenges and opportunities presented by the Swiss…

Switzerland Founded in 2020 with a focus on diseases related to skeletal muscle damage, MUVON Therapeutics is currently targeting a significant unmet need in women’s health, Female Stress Urinary Incontinence (SUI). CEO & co-founder Deana Mohr-Haralampieva, outlines MUVON’s progress into phase II clinical trials and its plans to raise EUR 65…

Switzerland Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba discusses the promising therapeutic areas Engimmune is targeting—particularly liver cancer and immunology—and the company’s unique technology that harnesses soluble T-cell…

Switzerland Myriam DeLeone, General Manager of Amgen Switzerland, discusses the company’s commitment to tackling diseases prevalent in Switzerland such cardiovascular diseases and osteoporosis, Amgen’s expanding biosimilars profile, and how the company is leveraging Artificial Intelligence (AI), particularly to optimize drug development. DeLeone also comments on Switzerland’s concerning deficiencies in digitalization and access,…

Switzerland Dimitri Gitas, Managing Director of MSD Switzerland, discusses the strategic importance of Switzerland, not only as a management hub for the company, but as a manufacturing location and clinical research centre where its clinical trials have grown to over 60 per year. Gitas also shares MSD’s key focus areas in…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Switzerland Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s internal research, clinical trials, and recent product launches, along with their ambitions to double European revenues in the coming years.…

LatAm An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s Celnova Pharma; Grifols’ distribution deal with Gema Biotech; the downturn in Uruguay’s medicinal canibis industry, and Novartis’ increased clinical trial…

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

Switzerland Ernst Niemack, managing director of vips, the association representing pharmaceutical companies operating in Switzerland, comments on the government’s latest cost containment measures such as mandatory rebates and new rules for biosimilars and generics, and the impact of these policies on innovative pharma. He also discusses the lag between registrations and…

Switzerland After heading up AstraZeneca Switzerland for one year, Florian Saur reflects on his career journey, discusses the Swiss market and how the country, despite its advanced healthcare and research ecosystem, has fallen behind in terms of access to innovation and digitalization. He shares the ambitious plans to launch 35 new…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…